Kandrozid

Candesartan cilexetil, the active ingredient in Kandrozid, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It is prescribed to manage high blood pressure and related cardiovascular conditions in adult patients, including heart failure and diabetic kidney disease.

GNH USA supplies Kandrozid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets.

Kandrozid, an angiotensin II receptor blocker, is used to treat conditions related to the renin‑angiotensin system.

Hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk. Heart failure: improves symptoms and decreases hospitalization in patients with reduced ejection fraction. Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes.

Candesartan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Upper respiratory tract infection - Abdominal discomfort - Back pain

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Acute renal impairment or failure - Severe hypotension - Hyperkalemia (elevated blood potassium) - Hepatic injury or jaundice - Severe allergic reactions (e.g., Stevens‑Johnson syndrome)

Before initiating therapy, clinicians should consider several safety measures.

Monitor blood pressure: ensure adequate control without excessive lowering. Assess renal function: check serum creatinine and eGFR periodically. Check serum potassium: avoid hyperkalaemia, especially with potassium‑sparing agents. Avoid use in pregnancy: drug is classified as Category D. Use caution in elderly patients: start at lower doses and monitor for orthostatic effects. Store at below 25°C: keep in the original pack, protect from moisture.

Candesartan can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients: increased risk of renal dysfunction. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalaemia. - ACE inhibitors or other ARBs: additive effect on renal function and potassium levels.

Moderate Interactions (Monitor Closely): - Loop or thiazide diuretics: may require dose adjustment of antihypertensive therapy. - Rifampin or other CYP3A4 inducers: can reduce candesartan plasma concentrations. - Lithium: candesartan may increase lithium levels, necessitating close monitoring.